FDA told OrganiCare of Austin, Texas that its HClear for him and FemiClear Genital Herpes Symptoms ointments are unapproved new drugs.
What happened
FDA reviewed the company's website, femiclear.com, in July 2026, along with its Facebook and Instagram pages that link to the site. FDA found the two ointments sold as treatments for genital herpes symptoms, with claims that they kill 99.9% of herpes simplex viruses and testimonials from users. FDA says no over-the-counter drug is approved to treat, cure or prevent any sexually transmitted infection.
What FDA found
The website and social media posts claim the ointments relieve genital herpes symptoms and kill herpes viruses, which makes them drugs in FDA's view.
Section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1); 21 CFR 201.128The products are new drugs because they are not generally recognized as safe and effective for these uses, and FDA has approved no application for them.
Section 201(p) and 505(a) of the FD&C Act, 21 U.S.C. 321(p) and 355(a)Shipping these unapproved drugs between states is against the law.
Sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a)Calling the products homeopathic does not exempt them from drug approval rules, and they contain lemongrass, which is not listed in the Homeopathic Pharmacopeia of the United States.
Customer testimonials on the product page describing the ointment clearing herpes blisters count as evidence the product is meant to treat disease.
Section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1)
What FDA wants
FDA tells the company to find the root causes, take corrective and preventive steps, and send a written response with documentation to FDAAdvisory@fda.hhs.gov within 15 business days, citing reference number 734925.
Who should pay attention
- brands making disease-treatment claims for 'natural' or homeopathic topical products
- retailers and online marketplaces that list these products
- companies whose websites and social media carry customer testimonials about treating disease
This is a summary. Read the original letter on fda.gov.